The Novo Nordisk Way is a global commitment that defines who we are, where we want to go and the values that characterize our company. It is a promise we make to each other and our external stakeholders.
Producing life-saving medicines is a significant responsibility: millions of people depend on us. However, to defeat a serious chronic condition, we need to do more than supply the right medicine. This is why we work in partnerships with multiple stakeholders to raise awareness, improve prevention, promote earlier diagnosis and expand access to care.
As part of the Novo Nordisk Way, we are committed to being transparent about our interactions, especially those with research organizations, teaching hospitals, health care professionals and the overall medical community. We follow the highest ethical standards as well as all legal and regulatory requirements in our interactions with the medical community and our customers.
The Physician Payments Sunshine Act (Sunshine Act), which is part of the Affordable Care Act, requires pharmaceutical manufacturers to annually report to the Center for Medicare and Medicaid Services (CMS) certain payments and transfers of value to health care professionals and teaching hospitals. The Sunshine Act promotes transparency by publishing the financial relationships between pharmaceutical manufacturers, HCPs and teaching hospitals on a publicly accessible website developed by the Centers for Medicare & Medicaid Services (CMS).
Novo Nordisk supports and adheres to all requirements of The Sunshine Act and submits its annual Sunshine transaction report to CMS as required by law.
For more information on The Sunshine Act and Novo Nordisk’s engagement with healthcare providers, please contact the Compliance Department at NNISunshineCompliance@novonordisk.com.